Summary:
The Ear Science Institute Australia’s project on sensorineural hearing loss treatment has been chosen by MedChem Australia to receive support for drug discovery from medicinal chemistry and pharmacokinetics experts.
Key Takeaways:
- Expert Collaboration: The project, led by Adj. A/Prof. Elaine Wong and Prof. Marcus Atlas, will collaborate with MedChem Australia and other institutions to develop novel treatments for sensorineural hearing loss.
- Support from MedChem Australia: This inclusion provides the project with vital support from MedChem Australia’s experts in medicinal chemistry and pharmacokinetics, aiding in drug discovery and development.
- Broad Research Impact: MedChem Australia’s initiative includes other projects targeting various diseases such as cancers, heart disease, and genetic disorders.
An Ear Science Institute Australia project on sensorineural hearing loss treatment has been selected by MedChem Australia to be included in the first round of Portfolio and Pilot projects that will receive support with the provision of medicinal chemistry and pharmacokinetics expertise for promising drug discovery programs tackling a range of diseases.
The project leads are Adj. A/Prof. Elaine Wong and Prof. Marcus Atlas from Ear Science Institute Australia, in collaboration with Dr. Victor Chuang Honorary Fellow at Ear Science, Prof. Lee Yong Lim and A/Prof. Connie Locher from UWA.
Further Reading: National Acoustics Laboratories and Ear Science Institute Australia Announce Collaboration
As a pilot project, the novel small molecules for treatment of sensorineural hearing loss project stands to benefit from the expertise of drug discovery for sensorineural hearing loss that will pave the way to reduce the health burden of hearing disorders.
Commenting on the selection, project lead Wong says, “I am very privileged to lead this ground-breaking research program and collaborate with MedChem teams at Monash University and WEHI to develop a new therapeutic intervention for hearing loss.”
Headquartered at the Monash Institute of Pharmaceutical Sciences in Parkville, MedChem Australia is a partnership between Monash University, WEHI, University of Sydney, and Therapeutic Innovation Australia, with support from the Australian federal government’s Medical Research Future Fund.
MedChem Australia Director Professor Brendon Monahan says each selected project aligns with MedChem Australia’s goal to facilitate the translation of cutting-edge research into tangible advancements in drug discovery. “Our thanks to everyone who submitted an application,” he says. “We congratulate the successful applicants for their outstanding proposals and look forward to working with them to progress the projects towards becoming much-needed new safe and effective medicines that can transform the lives of people and communities around the world.
“Collaboration and multi-disciplinary teams are essential in developing new therapies. Our experienced drug hunters are able to contribute to these projects in a way that will add real value and set them up for success down the track,” Professor Monahan says.
Other selected projects are seeking to develop new therapeutic interventions for different cancers, heart disease, a pediatric genetic disorder, and obesity.
